Owlstone Medical has announced the publication of a peer-reviewed study that identifies a set of volatile organic compounds that can identify patients with liver disease and separate them based on severity.

MIP Discovery has announced it has secured a significant grant of funds from the Bill & Melinda Gates Foundation.

Beckman Coulter Life Sciences further strengthens its commitment to the greater Loveland, Colorado community with the completion of the first phase of its new research and development hub.

Isohelix (UK) announces that it has commenced engagement with the U.S. Food and Drug Administration to progress the full regulatory approval of the GeneFix® Saliva DNA Collectors into the USA.

Mainz Biomed has received approval from an independent Institutional Review Board for the protocol ReconAAsense, the Company’s US pivotal study to evaluate the clinical performance of its highly efficacious and easy-to-use detection test for colorectal cancer.

Thermo Fisher Scientific has introduced over 50 new Absolute Q Liquid Biopsy Assays to run on the Applied Biosystems QuantStudio Absolute Q dPCR System.

Thermo Fisher Scientific has updated its Applied Biosystems 3500 and 3500xL DX genetic analyzers to comply with IVDR regulations.

Personalis has announced a collaboration with UC San Francisco that will deploy a personalized liquid biopsy-based research use only assay for a study of patients with colorectal cancer.

Mainz Biomed has announced the initiation of eAArly DETECT, its US extension of ColoFuture, which is the Company’s European feasibility study evaluating the integration of a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert.

Arima Genomics, Inc. has announced that new data on the detection of actionable structural variants from cancer samples embedded in formalin-fixed, paraffin-embedded tissues will be presented at the Association of Molecular Pathology Annual Meeting.